SR One, the corporate venturing unit of UK-listed pharmaceutical company GlaxoSmithKline, has reinvested in the consortium backing US drugs company Constellation Pharmaceuticals’ $15m series B round extension.
Venture capital firms Third Rock Ventures, The Column Group, Venrock Associates, and Altitude Life Science Ventures also participated in the B extension. Altitude invests on behalf of the Southern Ute Indian Tribe, and counts Steve Johnson, formerly president of corporate venturing unit Tredegar Investments, among its members.
SR One led Constellation’s $22m B round last year, which followed $32m raised historically.
Constellation looks to discover and develop therapies for the treatment of cancer, inflammatory and immune disorders as well as other diseases using epigenetics, the study of hereditary genes.
Mark Goldsmith, executive president of Constellation Pharmaceuticals, said: "This additional funding enables us to continue leveraging our expertise in chromatin [which controls gene functioning and DNA replication] biology to expand our growing product pipeline, and it provides strategic flexibility as we execute our overall development and business plans."
It is the second deal in three weeks for SR One, which last month led a $15m series B financing of biological drugs company SpringLeaf Therapeutics.